

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業（開曼）控股有限公司

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 6998)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Genor Biopharma Holdings Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 28 March 2025 for the purpose of considering and approving, among other matters, the annual results of the Company and its subsidiaries for the year ended 31 December 2024 and its publication.

By order of the Board
Genor Biopharma Holdings Limited
Mr. Weng Chengyi
Executive Director and Chief Financial Officer

Hong Kong, 18 March 2025

As at the date of this announcement, the Board comprises seven (7) Directors, namely Mr. WENG Chengyi (Chief Financial Officer) as an executive Director; Dr. LYU Dong, Mr. YU Tieming and Mr. LIU Yi as non-executive Directors; and Ms. CUI Bai, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive Directors.